IP Verse

Antigen-Binding Molecule Capable Of Binding To Two Or More Antigen Molecules Repeatedly - EP2708559

The patent EP2708559 was granted to Chugai Seiyaku Kabushiki Kaisha on Mar 28, 2018. The application was originally filed on Apr 10, 2009 under application number EP13195718A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2708559

CHUGAI SEIYAKU KABUSHIKI KAISHA
Application Number
EP13195718A
Filing Date
Apr 10, 2009
Status
Granted And Under Opposition
Feb 23, 2018
Grant Date
Mar 28, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALEXION PHARMACEUTICALSDec 31, 2018J A KEMPWITHDRAWN
ABLYNXDec 21, 2018HOFFMANN EITLEADMISSIBLE
SHIRE HUMAN GENETIC THERAPIESDec 21, 2018HOFFMANN EITLEADMISSIBLE
JAMES POOLEDec 19, 2018CARPMAELS & RANSFORDADMISSIBLE
NOVO NORDISKDec 19, 2018J A KEMPADMISSIBLE
GLAXO GROUPDec 18, 2018HITCHCOCKADMISSIBLE

Patent Citations (56) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0125023
DESCRIPTIONEP0239400
DESCRIPTIONJPH0159878B
DESCRIPTIONJPH10504970
DESCRIPTIONUS2007280945
DESCRIPTIONWO0061739
DESCRIPTIONWO02079255
DESCRIPTIONWO0220565
DESCRIPTIONWO0231140
DESCRIPTIONWO0232925
DESCRIPTIONWO03002609
DESCRIPTIONWO03105757
DESCRIPTIONWO2004039826
DESCRIPTIONWO2004044011
DESCRIPTIONWO2004058821
DESCRIPTIONWO2005037989
DESCRIPTIONWO2005040229
DESCRIPTIONWO2006067847
DESCRIPTIONWO2006067913
DESCRIPTIONWO2007014278
DESCRIPTIONWO2007059782
DESCRIPTIONWO2007142325
DESCRIPTIONWO9201047
DESCRIPTIONWO9203918
DESCRIPTIONWO9220791
DESCRIPTIONWO9306213
DESCRIPTIONWO9311236
DESCRIPTIONWO9312227
DESCRIPTIONWO9319172
DESCRIPTIONWO9402602
DESCRIPTIONWO9501438
DESCRIPTIONWO9501937
DESCRIPTIONWO9515388
DESCRIPTIONWO9515393
DESCRIPTIONWO9602576
DESCRIPTIONWO9633735
DESCRIPTIONWO9634096
DESCRIPTIONWO9813388
DESCRIPTIONWO9954342
EXAMINATIONWO03105757
EXAMINATIONWO2009139822
OPPOSITIONEP2275443
OPPOSITIONJP2008104147
OPPOSITIONUS2003059937
OPPOSITIONUS2005260711
OPPOSITIONUS5501854
OPPOSITIONUS5830478
OPPOSITIONWO03105757
OPPOSITIONWO03107009
OPPOSITIONWO2008043822
OPPOSITIONWO2009139822
OPPOSITIONWO2011111007
OPPOSITIONWO9112023
OPPOSITIONWO9720858
SEARCHUS2003059937
SEARCHWO2011111007

Non-Patent Literature (NPL) Citations (147) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- AMINO ACIDS, (1999), vol. 16, no. 3-4, pages 345 - 79-
DESCRIPTION- AMIT ET AL., SCIENCE, (1986), vol. 233, pages 747 - 53-
DESCRIPTION- ANGEW. CHEM. INT. ED., (2005), vol. 44, page 34-
DESCRIPTION- BETTER, M.; HORWITZ, A. H., METHODS IN ENZYMOLOGY, (1989), vol. 178, pages 476 - 496-
DESCRIPTION- BIOCHEM. BIOPHYS. RES. COMMUN., (20050909), vol. 334, no. 4, pages 1004 - 13-
DESCRIPTION- BIOTECHNOL. PROG., (200203), vol. 18, no. 2, pages 212 - 20-
DESCRIPTION- BIRD, R. E. ET AL., TIBTECH, (1991), vol. 9, pages 132 - 137-
DESCRIPTION- CANCER RES., (19930215), vol. 53, no. 4, pages 851 - 6-
DESCRIPTION- CHEM SOC REV., (20040910), vol. 33, no. 7, pages 422 - 30-
DESCRIPTION- CHOTHIA ET AL., J. MOL. BIOL., (1987), vol. 196, pages 901 - 17-
DESCRIPTION- CHOTHIA ET AL., NATURE, (1989), vol. 342, page 877-
DESCRIPTION- CLACKSON ET AL., NATURE, (1991), vol. 352, pages F24 - 8-
DESCRIPTION- CLIN PHARMACOL., (200804), vol. 48, no. 4, pages 406 - 17-
DESCRIPTION- CO, M.S. ET AL., J. IMMUNOL., (1994), vol. 152, pages 2968 - 2976-
DESCRIPTION- COX HM ET AL., NAT. BIOTECHNOL., (200612), vol. 24, no. 12, pages 1591 - 1597-
DESCRIPTION- CURRENT OPINION IN BIOTECHNOLOGY, (2006), vol. 17, pages 653 - 658-
DESCRIPTION- CURRENT OPINION IN BIOTECHNOLOGY, (2007), vol. 18, pages 1 - 10-
DESCRIPTION- CURRENT OPINION IN STRUCTURAL BIOLOGY, (1997), vol. 7, pages 463 - 469-
DESCRIPTION- EBERT ET AL., BIO/TECHNOLOGY, (1994), vol. 12, pages 699 - 702-
DESCRIPTION- EMBO J., (19941215), vol. 13, no. 24, pages 5863 - 70-
DESCRIPTION- EUR. J. IMMUNOL., (1993), vol. 23, pages 2026 - 2029-
DESCRIPTION- FEBS LETTER, (1992), vol. 305, no. 1, pages 85 - 88-
DESCRIPTION- FEBS-LETTER, (1992), vol. 309, no. 1, page 8588-
DESCRIPTION- FEES LETTER, (1992), vol. 309, no. I, pages 85 - 88-
DESCRIPTION- G. KOHLER; C. MILSTEIN, METHODS ENZYMOL., (1981), vol. 73, pages 3 - 46-
DESCRIPTION- GODING, Monoclonal Antibodies: Principles and Practice, ACADEMIC PRESS, (1986), pages 59 - 103-
DESCRIPTION- GRIFFITHS ET AL., EMBO J., (1994), vol. 13, pages 324.0 - 60-
DESCRIPTION- HIBI ET AL., CELL, (1990), vol. 63, pages 1149 - 1157-
DESCRIPTION- HINTON PR; XIONG JM; JOHLFS MG; TANG MT; KELLER S; TSURUSHITA N, "An engineered human IgG1 antibody with longer serum half-life", J IMMUNOL., (20060101), vol. 176, no. 1, pages 346 - 56-
DESCRIPTION- HIRATA ET AL., FEBS LETTER, (1994), vol. 356, pages 244 - 248-
DESCRIPTION- HUSTON, J. S. ET AL., PROC. NATL. ACAD. SCI. U.S.A., (1988), vol. 10.0, pages 5879 - 5883-
DESCRIPTION- J. ALLERGY AND CLINICAL FNMUNOLOGY, (1997), vol. 100, no. 1, pages 110 - 121-
DESCRIPTION- J. BIOCHEM., (1990), vol. 108, pages 673 - 676-
DESCRIPTION- J BIOL CHEM., (20010302), vol. 276, no. 9, pages 6591 - 604-
DESCRIPTION- J. EXP. MED., (1995), vol. 1Q8, page 94.0-
DESCRIPTION- J. IMMUNOL. METHODS, (19970623), vol. 205, no. 1, pages 67 - 72-
DESCRIPTION- J. IMMUNOL. METHODS, (20010101), vol. 247, no. 1-2, pages 191 - 203-
DESCRIPTION- J. IMMUNOL. METHODS, (20080320), vol. 332, no. 1-2, pages 2 - 9-
DESCRIPTION- J. IMMUNOLOGICAL METHODS, (1999), vol. 231, pages 119 - 135-
DESCRIPTION- J. MOL. BIOL., (1992), vol. 227, pages 381 - 388-
DESCRIPTION- J. MOL. BIOL., (1996), vol. 256, pages 77 - 88-
DESCRIPTION- J MOL BIOL., (20080229), vol. 376, no. 4, pages 1182 - 200-
DESCRIPTION- J. NATIONAL CANCER INSTITUTE, (2002), vol. 94, no. 19, pages 1484 - 1493-
DESCRIPTION- KIDNEY INT., (2003), vol. 64, pages 697 - 703-
DESCRIPTION- KIM SJ; PARK Y; HONG HJ, "Antibody engineering for the development of therapeutic antibodies", MOL CELLS., (20050831), vol. 20, no. 1, pages 17 - 29, XP055199890-
DESCRIPTION- K. SATO ET AL., CANCER RES., (1993), vol. 53, pages 10.01 - 10.06-
DESCRIPTION- KUNKEL, PROC. NATL. ACAD. SCI. USA, (1910), vol. 82, page 488-
DESCRIPTION- LAMOYI, E., METHODS IN ENZYMOLOGY, (1989), vol. 121, pages 652 - 663-
DESCRIPTION- MA ET AL., EUR. J. IMMUNOL., (1994), vol. 24, pages 131 - 138-
DESCRIPTION- MARKS ET AL., J. MOL. BIOL., (1991), vol. 222, pages 581 - 97-
DESCRIPTION- MENDEZ ET AL., NAT. GENET, (1997), vol. 15, pages 146 - 56-
DESCRIPTION- MOL. CELL., (200104), vol. 7, no. 4, pages 867 - 77-
DESCRIPTION- MOL CELL BIOL., (1988), vol. 8, pages 466 - 472-
DESCRIPTION- NAT BIOTECHNOL., (200509), vol. 23, no. 9, pages 1126 - 36-
DESCRIPTION- NAT. BIOTECHNOL., (200509), vol. 23, no. 9, pages L 126 - 36-
DESCRIPTION- NAT. CLIN. PRACT. RHEUMATOL., (200611), vol. 2, no. 11, pages 619 - 26-
DESCRIPTION- NAT MED. 2003 BIODRUGS, (2006), vol. 20, no. 3, pages 151 - 60-
DESCRIPTION- NAT. REV. IMMUNOL., (200709), vol. 7, no. 9, pages 715 - 25-
DESCRIPTION- NAT REV MOL CELL BIOL., (200402), vol. 5, no. 2, pages 121 - 32-
DESCRIPTION- NAT. REV. MOL. CELL. BIOL., (200402), vol. 5, no. 2, pages 121 - 32-
DESCRIPTION- NATURE BIOTECHNOLOGY, (200012), vol. 18, pages 1287 - 1292-
DESCRIPTION- PHARM RES., (200601), vol. 23, no. L, pages 95 - 103-
DESCRIPTION- PLUECKTHUN, A.; SKERRA, A., METHODS IN ENZYMOLOGY, (1989), vol. 178, pages 497 - 515-
DESCRIPTION- PROC. NATL. ACAD. SCI. USA, (19950523), vol. 92, no. 11, pages 4862 - 6-
DESCRIPTION- PROC NATL ACAD SCI U S A., (20060314), vol. 103, no. 11, pages 4005 - 10-
DESCRIPTION- PROTEIN SCIENCE, (1995), vol. 4, pages 2411 - 2423-
DESCRIPTION- PROTEIN SCIENCE, (2006), vol. 15, pages 14 - 27-
DESCRIPTION- ROUSSEAUX, J. ET AL., METHODS IN ENZYMOLOGY, (1989), vol. 121, pages 663 - 66-
DESCRIPTION- SATO, K. ET AL., CANCER RES., (1993), vol. 53, pages 10.01 - 6-
DESCRIPTION- THE JOURNAL OF RHEUMATOLOGY, (2003), vol. 30, pages 71426 - 1435-
DESCRIPTION- VALLE ET AL., NATURE, (1981), vol. 291, pages 338 - 340-
DESCRIPTION- VAUGHAN ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 309 - 14-
DESCRIPTION- WATERHOUSES ET AL., NUCLEIC ACIDS RES., (1993), vol. 21, pages 2265 - 6-
DESCRIPTION- YAMASAKI ET AL., SCIENCE, (1988), vol. 241, pages 825 - 828-
DESCRIPTION- RATHANASWAMI P; ROALSTAD S; ROSKOS L; SU QJ; LACKIE S; BABCOOK J, "Demonstration of an in vivo generated sub-picomolar affinity fully human monoclonal antibody to interieukin-8", BIOCHEM BIOPHYS RES COMMUN., (20050909), vol. 334, no. 4, doi:doi:10.1016/j.bbrc.2005.07.002, pages 1004 - 13, XP027459137
DESCRIPTION- HANSON CV; NISHIYAMA Y; PAUL S., "Catalytic antibodies and their applications", CURR OPIN BIOTECHNOL., (200512), vol. 6, no. 6, doi:doi:10.1016/j.copbio.2005.10.003, pages 631 - 6, XP005173495
DESCRIPTION- PAVLOU AK; BELSEY MJ, "The therapeutic antibodies market to 2008", EUR J PHARM BIOPHARM., (200504), vol. 59, no. 3, doi:doi:10.1016/j.ejpb.2004.11.007, pages 389 - 96, XP025317626
DESCRIPTION- WU H; PFARR DS; JOHNSON S; BREWAH YA; WOODS RM; PATEL NK; WHITE WI; YOUNG JF; KIENER PA, "Development of Motavizumab, an Ultra-potent Antibody for the Prevention of Respiratory Syncytial Virus Infection in the Upper and Lower Respiratory Tract", J MOL BIOL., (2007), vol. 368, doi:doi:10.1016/j.jmb.2007.02.024, pages 652 - 665, XP022020027
DESCRIPTION- GHETIE V; POPOV S; BORVAK J; RADU C; MATESOI D; MEDESAN C; OBER RJ; WARD ES, "Increasing the serum persistence of an IgG fragment by random mutagenesis", NAT BIOTECHNOL., (199707), vol. 15, no. 7, doi:doi:10.1038/nbt0797-637, pages 637 - 40, XP000876642
DESCRIPTION- JANICE M REICHERT; CLARK J ROSENSWEIG; LAURA B FADEN; MATTHEW C DEWITZ, "Monoclonal antibody successes in the clinic", NATURE BIOTECHNOLOGY, (2005), vol. 23, doi:doi:10.1038/nbt0905-1073, pages 1073 - 1078, XP002555770
DESCRIPTION- RAJPAL A; BEYAZ N; HABER L; CAPPUCCILLI G; YEE H; BHATT RR; TAKEUCHI T; LERNER RA; CREA R, "A general method for greatly improving the affinity of antibodies by using combinatorial libraries", PROC NATL ACAD SCI U S A., (20050606), vol. 102, no. 24, doi:doi:10.1073/pnas.0503543102, pages 8466 - 71, XP002392777
OPPOSITION- ABOUD-PIRAK E et al., "Binding and Endocytosis of a Monoclonal Antibody to a High Molecular Weight Human Milk Fat Globule Membrane-associated Antigen by Cultured MCF-7 Breast Carcinoma Cells", Cancer Research, (19880000), vol. 48, pages 3188 - 3196, XP055540350-
OPPOSITION- ABOUD-PIRAK et al., "Binding and Endocytosis of a Monoclonal Antibody to a High Molecular Weight Human Milk Fat Globule Membrane-associated Antigen by Cultured MCF-7 Breast Carcinoma Cells1", Cancer Research, (19980000), vol. 48, pages 3188 - 3196, XP055540350-
OPPOSITION- ANCHIN et al., "Recognition of Superpotent sweetner ligands by a library of monoclonal antibodies", Journal of Molecular Recognition, (19970000), vol. 10, pages 235 - 242, XP055540314-
OPPOSITION- CLELAND et al., "Formulation and Delivery of Proteins and Peptides", ACS Symposium Series, Washington D.C, (19940000), XP055543220-
OPPOSITION- HUGHES-JONES et al., "THE EFFECT OF PH AND IONIC STRENGTH ON THE REACTION BETWEEN ANTI-D AND ERYTHROCYTES", Immunology, (19640000), vol. 7, no. 1, pages 72 - 81, XP055543177-
OPPOSITION- IGAWA et al., "Engineering the variable region of therapeutic IgG antibodies", MAbs, (20110500), vol. 3, no. 3, pages 243 - 252, XP009153597-
OPPOSITION- ITO et al., "The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS, (19920800), vol. 309, no. 1, pages 85 - 55, XP008123385-
OPPOSITION- ITO et al., "The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS, (19920800), vol. 309, no. 1, pages 85 - 88, XP008123385-
OPPOSITION- ITO et al., "The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS Lett., (19920831), vol. 309, no. 1, pages 85 - 88, XP008123385-
OPPOSITION- ITO et al., "The His-probe method: effects of histidine residues introduced into the complementarity-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS Letters., (19920000), vol. 309, no. 1, pages 85 - 88, XP008123385-
OPPOSITION- KING et al., "Antibody Engineering: Design for Specific Applications", Applications and Engineering of Monoclonal Antibodies, (19980000), pages 27 - 75, XP055543185-
OPPOSITION- KRANZ et al., "Mechanisms of Ligand Binding by Monoclonal Anti-fluorescyl Antibodies", J. Biol. Chem., (19820000), vol. 257, no. 12, pages 6987 - 6995, XP055435543-
OPPOSITION- MAXFIELD et al., "Endocytic recycling", Nat Rev Mol Cell Biol., (20040200), vol. 5, no. 2, pages 121 - 132, XP009151548-
OPPOSITION- "Product Information Sheet", SIGMA, (19980000), XP055542989-
OPPOSITION- "Promega Protocols and Applications Guide", Promega, (19910000), XP055544058-
OPPOSITION- "Rituximab", product information, IDEC, (19970000), XP055543213-
OPPOSITION- "Rituximab", Wikipedia, (20181024), pages 1 - 7, XP055543215-
OPPOSITION- SATO et al., "Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth", Cancer Research, (19930000), vol. 53, no. 4, pages 851 - 856, XP002009993-
OPPOSITION- SHADDUCK RK et al., "Fractionation of Antibodies to L-Cell Colony Stimulating Factor by Affinity Chormatography", Blood, (19790000), vol. 53, no. 6, pages 1182 - 1190, XP055543106-
OPPOSITION- MURTAUGH et al., "A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches", Protein Sci., (20110900), vol. 20, no. 9, pages 1619 - 1631, XP055011183
OPPOSITION- NARHI et al., "Effect of three elution buffers on the recovery and structure of monoclonal antibodies", Anal Biochem., (19971115), vol. 253, no. 2, pages 236 - 245, XP002357750
OPPOSITION- DRAKE et al., Biophysical Consideration for Development of Antibody-Based Therapeutics, (20120100), vol. 95-97, pages 95 - 97, XP055100977
OPPOSITION- CHANG BS et al., "Practical approaches to protein formulation development", Rational Design of stable protein formulations - theory and practice (chapter 1, New York, (20020000), pages 1 - 25, XP055543078
OPPOSITION- SADA et al., "Effect of histidine residues in antigenic sites on pH dependence of immune- adsorption equilibrium", Appl Micorbiol Biotechnol, (19880000), vol. 27, no. 5-6, pages 528 - 532, XP009153724
OPPOSITION- LEE et al., "High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold", J Mol Biol., (20040723), vol. 340, no. 5, pages 1073 - 1093, XP002716293
OPPOSITION- HUSE et al., "Purification of antibodies by affinity chromatography", J. Biochem.Biophys. Methods, (20020000), vol. 51, no. 3, pages 217 - 231, XP002414578
OPPOSITION- MAEDA et al., "pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes", J Control Release, (20020718), vol. 82, no. 1, pages 71 - 82, XP004369791
OPPOSITION- HARRIS et al., "Identification of multiple sources of charge heterogeneity in a recombinant antibody", J Chromatogr B Biomed Sci Appl., (20010310), vol. 752, no. 2, pages 233 - 245, XP002682609
OPPOSITION- WANG, "Instability, stabilization, and formulation of liquid protein pharmaceuticals", International Journal of Pharmaceutics, (19990000), vol. 185, no. 2, pages 129 - 188, XP002323952
OPPOSITION- MARTIN et al., "Crystal Structure at 2.8A of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding", Mol Cell, (20010400), vol. 7, no. 4, pages 867 - 877, XP003027710
OPPOSITION- MARSHALL et al., "Rational design and engineering of therapeutic proteins", Drug Discovery Today, (20030000), vol. 8, no. 5, pages 212 - 221, XP002295833
OPPOSITION- MARSHALL et al., "Rational design and engineering of therapeutic proteins", therapeutic focus, DDT, (20030300), vol. 8, no. 5, pages 212 - 221, XP002295833
OPPOSITION- TABRIZI et al., "Elimination mechanisms of therapeutic monoclonal antibodies", Drug Discovery T, (20060100), vol. 11, no. 1-2, pages 81 - 88, XP005290126
OPPOSITION- TABRIZI et al., "Elimination mechanisms of therapeutic monoclonal antibodies", Drug Discov Today, (20060100), vol. 11, no. 1-2, pages 81 - 88, XP005290126
OPPOSITION- BURMEISTER et al., "Crystal structure of the complex of rat neonatal Fc receptor with FC", Nature, (19941124), vol. 372, pages 379 - 383, XP000876647
OPPOSITION- IGAWA et al., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nat Biotechnol., (20101100), vol. 28, no. 11, pages 1203 - 1208, XP009153598
OPPOSITION- IGAWA et al., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", Nature Biotechnology, (20100000), vol. 28, no. 11, pages 1203 - 1208, XP009153598
OPPOSITION- IGAWA et al., "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", nature biotechnology , Letters, (20101111), no. 28, pages 1203 - 1208, XP009153598
OPPOSITION- SARKAR et al., "Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching"", Nat Biotechnol., (20020900), vol. 20, no. 9, pages 908 - 913, XP002657852
OPPOSITION- SARKAR et al., "Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching"", Nature Biotechnology, (20020000), vol. 20, no. 9, pages 908 - 913, XP002657852
OPPOSITION- SARKAR et al., "Rational cytokine design for increased lifetime and enhanced potency using pH-activated "histidine switching"", nature biotechnology, (20020900), vol. 20, no. 9, pages 908 - 913, XP002657852
OPPOSITION- SARKAR et al., "Rational cytokine design for increasing lifetime and enhanced potency using pH-activated histidine switching", Nature Biotechnology, (20020900), vol. 20, no. 9, pages 908 - 913, XP002657852
OPPOSITION- ROOPENIAN et al., "FcRn: the neonatal Fc receptor comes of age", Nature Reviews, (20070907), vol. 7, pages 715 - 725, XP002510057
OPPOSITION- FISHER et al., "Affinity purification of antibodies using antigens immobilized on solid supports", Biochem. Society Transactions, (19980000), vol. 16, no. 2, pages 134 - 138, XP055540361
OPPOSITION- PATEL et al., "A Forgotten Cause of Kidney Injury in Chronic Myelomonocytic Leukemia", Am J Kidney Disease, (20090000), vol. 54, no. 1, pages 159 - 164, XP055543169
OPPOSITION- JUNGHANS et al., "The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor", Proc. Natl. Acad. Sci. USA., (19960000), vol. 93, pages 5512 - 5516, XP002130572
OPPOSITION- JUNGHANS et al., "The protection receptor for IgG catabolism is the beta2-microglobulin-containing neonatal intestinal transport receptor", Proc Natl Acad Sci USA., (19960528), vol. 93, no. 11, pages 5512 - 5516, XP002130572
OPPOSITION- RASO et al., "Antibodies capable of releasing diptheria toxin in response to the low pH found in endosomes", J Biol Chem, (19970000), vol. 272, no. 44, pages 27618 - 27633, XP002482522
OPPOSITION- RASO et al., "Antibodies capable of releasin g diptheria toxin in response to the low pH found in endosomes", Journal of Biological Chemistry, (19970000), vol. 272, no. 44, pages 27618 - 27622, XP002482522
OPPOSITION- RASO V et al., "Antibodies Capable of Releasing Diphtheria Toxin in Response to the Low pH Found in Endosomes", The Journal of Biological Chemistry, (19970000), vol. 272, no. 44, pages 27618 - 27622, XP002482522
OPPOSITION- VENTURI et al., "The monoclonal antibody 1F6 identifies a pH-dependent conformational change in the hydrophilic NH(2) terminus of NhaA Na(+)/H(+) antiporter of Escherichia coli", J. Biol. Chem., (20000000), vol. 275, no. 7, pages 4734 - 4742, XP055540354
OPPOSITION- IGAWA et al., "Reduced elimination of IgG antibodies by engineering the variable region", Protein Eng Des Sel., (20100500), vol. 23, no. 5, pages 385 - 392, XP055003115
OPPOSITION- KAMATA et al., "Comparison of pH and Ionic Strength Dependence of Interactions between Monoclonal Antibodies and Bovine .BETA.-Lactoglobulin", Biosci. Biotech. Biochem., (19960000), vol. 60, no. 1, pages 25 - 29, XP055540345
OPPOSITION- RASO, "Intracellular Targeting Using Bispecific Antibodies", Drug Targeting, Totowa, NJ, (20000000), pages 37 - 50, XP055542977
OPPOSITION- RASO V, "Intracellular Targeting Using Bispecific Antibodies. In: Francis GE, Delgado C (eds) Drug Targeting", Methods in Molecular Medicine, (20000000), vol. 25, pages 37 - 50, XP055542977
SEARCH- FREDERICK R MAXFIELD & TIMOTHY E MCGRAW, "Endocytic recycling", NATURE REVIEWS MOLECULAR CELL BIOLOGY, NATURE PUBLISHING, GB, (20040201), vol. 5, no. 2, ISSN 1471-0072, pages 121 - 132, XP009151548 [A] 1 * the whole document *-
SEARCH- IGAWA TOMOYUKI ET AL, "Engineering the variable region of therapeutic IgG antibodies", MABS, LANDES BIOSCIENCE, US, (20110501), vol. 3, no. 3, ISSN 1942-0870, pages 243 - 252, XP009153597 [T] * the whole document *-
SEARCH- ITO W ET AL, "The His-probe method: effects of histidine residues introduced into the complementary-determining regions of antibodies on antigen-antibody interactions at different pH values", FEBS LETTERS, ELSEVIER, AMSTERDAM, NL, (19920801), vol. 309, no. 1, ISSN 0014-5793, pages 85 - 88, XP008123385 [Y] 1,4,5 * the whole document *-
SEARCH- MEGAN L. MURTAUGH ET AL, "A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches", PROTEIN SCIENCE, (20110901), vol. 20, no. 9, doi:10.1002/pro.696, ISSN 0961-8368, pages 1619 - 1631, XP055011183 [T] * the whole document *
SEARCH- Andrew W Drake ET AL, "Biophysical Consideration for Development of Antibody-Based Therapeutics", Biophysical Consideration for Development of Antibody-Based Therapeutics, (20120101), pages 95 - 97, XP055100977 [AP] 1 * the whole document *
SEARCH- LEE C V ET AL, "High-affinity human antibodies from phage-displayed synthetic Fab libraries with a single framework scaffold", JOURNAL OF MOLECULAR BIOLOGY, ACADEMIC PRESS, UNITED KINGDOM, (20040723), vol. 340, no. 5, doi:10.1016/J.JMB.2004.05.051, ISSN 0022-2836, pages 1073 - 1093, XP002716293 [Y] 1,4,5 * the whole document *
SEARCH- MAEDA K ET AL, "pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, (20020718), vol. 82, no. 1, doi:10.1016/S0168-3659(02)00126-8, ISSN 0168-3659, pages 71 - 82, XP004369791 [A] 1 * The whole document, in particular section 3.1 and Fig.1 *
SEARCH- MARTIN W L ET AL, "Crystal Structure at 2.8A of an FcRn/Heterodimeric Fc Complex: Mechanism of pH-Dependent Binding", MOLECULAR CELL, CELL PRESS, CAMBRIDGE, MA, US, (20010401), vol. 7, doi:10.1016/S1097-2765(01)00230-1, ISSN 1097-2765, pages 867 - 877, XP003027710 [A] 1 * the whole document *
SEARCH- IGAWA T ET AL, "Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, (20101101), vol. 28, no. 11, doi:10.1038/NBT.1691, ISSN 1087-0156, pages 1203 - 1207, XP009153598 [T] * the whole document *
SEARCH- CASIM A SARKAR ET AL, "Rational cytokine design for increased lifetime and enhanced potency using pH-activated histidine switching", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 20, no. 9, doi:10.1038/NBT725, ISSN 1087-0156, (20020901), pages 908 - 913, (20020805), XP002657852 [Y] 1,4,5 * the whole document *
SEARCH- T. IGAWA ET AL, "Reduced elimination of IgG antibodies by engineering the variable region", PROTEIN ENGINEERING DESIGN AND SELECTION, (20100501), vol. 23, no. 5, doi:10.1093/protein/gzq009, ISSN 1741-0126, pages 385 - 392, XP055003115 [T] * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents